Cargando…
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06
PURPOSE: The O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611835/ https://www.ncbi.nlm.nih.gov/pubmed/37563351 http://dx.doi.org/10.1007/s00259-023-06371-5 |
_version_ | 1785128571905245184 |
---|---|
author | Barry, Nathaniel Francis, Roslyn J. Ebert, Martin A. Koh, Eng-Siew Rowshanfarzad, Pejman Hassan, Ghulam Mubashar Kendrick, Jake Gan, Hui K. Lee, Sze T. Lau, Eddie Moffat, Bradford A. Fitt, Greg Moore, Alisha Thomas, Paul Pattison, David A. Akhurst, Tim Alipour, Ramin Thomas, Elizabeth L. Hsiao, Edward Schembri, Geoffrey P. Lin, Peter Ly, Tam Yap, June Kirkwood, Ian Vallat, Wilson Khan, Shahroz Krishna, Dayanethee Ngai, Stanley Yu, Chris Beuzeville, Scott Yeow, Tow C. Bailey, Dale Cook, Olivia Whitehead, Angela Dykyj, Rachael Rossi, Alana Grose, Andrew Scott, Andrew M. |
author_facet | Barry, Nathaniel Francis, Roslyn J. Ebert, Martin A. Koh, Eng-Siew Rowshanfarzad, Pejman Hassan, Ghulam Mubashar Kendrick, Jake Gan, Hui K. Lee, Sze T. Lau, Eddie Moffat, Bradford A. Fitt, Greg Moore, Alisha Thomas, Paul Pattison, David A. Akhurst, Tim Alipour, Ramin Thomas, Elizabeth L. Hsiao, Edward Schembri, Geoffrey P. Lin, Peter Ly, Tam Yap, June Kirkwood, Ian Vallat, Wilson Khan, Shahroz Krishna, Dayanethee Ngai, Stanley Yu, Chris Beuzeville, Scott Yeow, Tow C. Bailey, Dale Cook, Olivia Whitehead, Angela Dykyj, Rachael Rossi, Alana Grose, Andrew Scott, Andrew M. |
author_sort | Barry, Nathaniel |
collection | PubMed |
description | PURPOSE: The O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation. METHODS: Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBR(max)), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR (TBR(max)/TBR(mean)) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]). RESULTS: Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBR(max), and TBR(mean) were 21.53% (12.00–30.10%), 5.89% (5.01–6.68%), and 5.01% (3.37–6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63–0.97) with good spatial (DSC = 0.84 ± 0.09) and boundary (HD = 15.78 ± 8.30 mm; MASD = 1.47 ± 1.36 mm) agreement. CONCLUSION: The FIG study credentialing program has increased expertise across study sites. TBR(max) and TBR(mean) were robust, with considerable variability in BTV delineation and image interpretation observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06371-5. |
format | Online Article Text |
id | pubmed-10611835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-106118352023-10-29 Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 Barry, Nathaniel Francis, Roslyn J. Ebert, Martin A. Koh, Eng-Siew Rowshanfarzad, Pejman Hassan, Ghulam Mubashar Kendrick, Jake Gan, Hui K. Lee, Sze T. Lau, Eddie Moffat, Bradford A. Fitt, Greg Moore, Alisha Thomas, Paul Pattison, David A. Akhurst, Tim Alipour, Ramin Thomas, Elizabeth L. Hsiao, Edward Schembri, Geoffrey P. Lin, Peter Ly, Tam Yap, June Kirkwood, Ian Vallat, Wilson Khan, Shahroz Krishna, Dayanethee Ngai, Stanley Yu, Chris Beuzeville, Scott Yeow, Tow C. Bailey, Dale Cook, Olivia Whitehead, Angela Dykyj, Rachael Rossi, Alana Grose, Andrew Scott, Andrew M. Eur J Nucl Med Mol Imaging Original Article PURPOSE: The O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation. METHODS: Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBR(max)), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR (TBR(max)/TBR(mean)) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]). RESULTS: Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBR(max), and TBR(mean) were 21.53% (12.00–30.10%), 5.89% (5.01–6.68%), and 5.01% (3.37–6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63–0.97) with good spatial (DSC = 0.84 ± 0.09) and boundary (HD = 15.78 ± 8.30 mm; MASD = 1.47 ± 1.36 mm) agreement. CONCLUSION: The FIG study credentialing program has increased expertise across study sites. TBR(max) and TBR(mean) were robust, with considerable variability in BTV delineation and image interpretation observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06371-5. Springer Berlin Heidelberg 2023-08-11 2023 /pmc/articles/PMC10611835/ /pubmed/37563351 http://dx.doi.org/10.1007/s00259-023-06371-5 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Barry, Nathaniel Francis, Roslyn J. Ebert, Martin A. Koh, Eng-Siew Rowshanfarzad, Pejman Hassan, Ghulam Mubashar Kendrick, Jake Gan, Hui K. Lee, Sze T. Lau, Eddie Moffat, Bradford A. Fitt, Greg Moore, Alisha Thomas, Paul Pattison, David A. Akhurst, Tim Alipour, Ramin Thomas, Elizabeth L. Hsiao, Edward Schembri, Geoffrey P. Lin, Peter Ly, Tam Yap, June Kirkwood, Ian Vallat, Wilson Khan, Shahroz Krishna, Dayanethee Ngai, Stanley Yu, Chris Beuzeville, Scott Yeow, Tow C. Bailey, Dale Cook, Olivia Whitehead, Angela Dykyj, Rachael Rossi, Alana Grose, Andrew Scott, Andrew M. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 |
title | Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 |
title_full | Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 |
title_fullStr | Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 |
title_full_unstemmed | Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 |
title_short | Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 |
title_sort | delineation and agreement of fet pet biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating fet pet in glioblastoma (fig) study—trog 18.06 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611835/ https://www.ncbi.nlm.nih.gov/pubmed/37563351 http://dx.doi.org/10.1007/s00259-023-06371-5 |
work_keys_str_mv | AT barrynathaniel delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT francisroslynj delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT ebertmartina delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT kohengsiew delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT rowshanfarzadpejman delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT hassanghulammubashar delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT kendrickjake delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT ganhuik delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT leeszet delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT laueddie delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT moffatbradforda delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT fittgreg delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT moorealisha delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT thomaspaul delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT pattisondavida delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT akhursttim delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT alipourramin delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT thomaselizabethl delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT hsiaoedward delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT schembrigeoffreyp delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT linpeter delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT lytam delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT yapjune delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT kirkwoodian delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT vallatwilson delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT khanshahroz delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT krishnadayanethee delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT ngaistanley delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT yuchris delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT beuzevillescott delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT yeowtowc delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT baileydale delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT cookolivia delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT whiteheadangela delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT dykyjrachael delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT rossialana delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT groseandrew delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 AT scottandrewm delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806 |